{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:03:44Z","timestamp":1781251424662,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"DOI":"10.7759\/cureus.110712","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:45:08Z","timestamp":1781250308000},"source":"Crossref","is-referenced-by-count":0,"title":["Repositioning Tradition: A Narrative Review and Expert Opinion on the Clinical Positioning of Glimepiride and Metformin in Nepal's Type 2 Diabetes Mellitus (T2DM) Landscape"],"prefix":"10.7759","author":[{"given":"Sabin","family":"Chaulagain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subesh","family":"Saurav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Malla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Kumar","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurav","family":"Khatiwada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taranath","family":"Koirala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aushili","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"The Diabetes Atlas. (2026). Accessed. June 2, 2026: https:\/\/diabetesatlas.org\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_556_17","article-title":"Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - international task force","volume":"22","author":"Kalra S","year":"2018","unstructured":"Kalra S, Bahendeka S, Sahay R, et al.. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - international task force. Indian J Endocrinol Metab. 2018, 22:132-57. 10.4103\/ijem.IJEM_556_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.53970.2","article-title":"Type 2 diabetes mellitus in Nepal from 2000 to 2020: a systematic review and meta-analysis","volume":"10","author":"Shrestha DB","year":"2021","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, et al.. Type 2 diabetes mellitus in Nepal from 2000 to 2020: a systematic review and meta-analysis. F1000Res. 2021, 10:543. 10.12688\/f1000research.53970.2","journal-title":"F1000Res"},{"key":"ref4","article-title":"Management of type 2 diabetes: selecting amongst available pharmacological agents","author":"Schroeder EB","year":"2026","unstructured":"Schroeder EB. Management of type 2 diabetes: selecting amongst available pharmacological agents. Endotext. Feingold KR, Adler RA, Ahmed SF, et al. (ed): MDText.com, Inc., South Dartmouth, MA; 2026."},{"key":"ref5","article-title":"Metformin","author":"Corcoran C","year":"2023","unstructured":"Corcoran C, Jacobs TF. Metformin. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112595","article-title":"Complementary yet distinct roles of GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular risk reduction","volume":"13","author":"Homor\u00f3di N","year":"2025","unstructured":"Homor\u00f3di N, Varga \u00c9, Szab\u00f3 Z, Sztanek F, Harangi M. Complementary yet distinct roles of GLP-1 receptor agonists and SGLT2 inhibitors in cardiovascular risk reduction. Biomedicines. 2025, 13:2595. 10.3390\/biomedicines13112595","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens PE","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, et al.. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105:S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-025-01582-6","article-title":"From glucose control to multifaceted benefits: the rise of modern sulphonylureas in diabetes care","volume":"25","author":"Shrestha D","year":"2025","unstructured":"Shrestha D, Dhingra A, Shakya S, Tuladhar J. From glucose control to multifaceted benefits: the rise of modern sulphonylureas in diabetes care. Curr Diab Rep. 2025, 25:28. 10.1007\/s11892-025-01582-6","journal-title":"Curr Diab Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00637-w","article-title":"Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort's analysis","volume":"11","author":"Bahardoust M","year":"2025","unstructured":"Bahardoust M, Mehrabi Y, Hadaegh F, Khalili D, Delpisheh A. Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort's analysis. Int J Retina Vitreous. 2025, 11:9. 10.1186\/s40942-025-00637-w","journal-title":"Int J Retina Vitreous"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01612-8","article-title":"Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review","volume":"15","author":"Sahin I","year":"2024","unstructured":"Sahin I, Bakiner O, Demir T, Sari R, Atmaca A. Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review. Diabetes Ther. 2024, 15:1687-716. 10.1007\/s13300-024-01612-8","journal-title":"Diabetes Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0651-1","article-title":"Glucocrinology of modern sulfonylureas: clinical evidence and practice-based opinion from an international expert group","volume":"10","author":"Kalra S","year":"2019","unstructured":"Kalra S, Das AK, Baruah MP, et al.. Glucocrinology of modern sulfonylureas: clinical evidence and practice-based opinion from an international expert group. Diabetes Ther. 2019, 10:1577-93. 10.1007\/s13300-019-0651-1","journal-title":"Diabetes Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310706","article-title":"Exploring the medicine cost of managing diabetes mellitus in Nepal: a cross-sectional analysis of oral hypoglycaemic medications","volume":"19","author":"Shrestha R","year":"2024","unstructured":"Shrestha R, Aryal A, Khatiwada AP, Dhungana S, Shrestha S. Exploring the medicine cost of managing diabetes mellitus in Nepal: a cross-sectional analysis of oral hypoglycaemic medications. PLoS One. 2024, 19:e0310706. 10.1371\/journal.pone.0310706","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.63682\/jns.v14i32S.7461","article-title":"A comparative assessment of safety, efficacy, and cost-effectiveness of glipizide-metformin and glimepiride-metformin combination therapy in type-2 diabetes mellitus","volume":"14","author":"Amargeeth S","year":"2025","unstructured":"Amargeeth S, Mathansekar R, CJ, et al.. A comparative assessment of safety, efficacy, and cost-effectiveness of glipizide-metformin and glimepiride-metformin combination therapy in type-2 diabetes mellitus. J Neonatal Surg. 2025, 14:801-9. 10.63682\/jns.v14i32S.7461","journal-title":"J Neonatal Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(02)85047-0","article-title":"Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy","volume":"24","author":"Melikian C","year":"2002","unstructured":"Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002, 24:460-7. 10.1016\/s0149-2918(02)85047-0","journal-title":"Clin Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12201","article-title":"Efficacy of glimepiride\/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: a randomized, open label, parallel group, multicenter study in Korea","volume":"5","author":"Kim HS","year":"2014","unstructured":"Kim HS, Kim DM, Cha BS, et al.. Efficacy of glimepiride\/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: a randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014, 5:701-8. 10.1111\/jdi.12201","journal-title":"J Diabetes Investig"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_22_18","article-title":"Commentary on \u201cconsensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: international task force\u201d","volume":"22","author":"Singh SK","year":"2018","unstructured":"Singh SK. Commentary on \u201cconsensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: international task force\u201d. Indian J Endocrinol Metab. 2018, 22:158-9. 10.4103\/ijem.IJEM_22_18","journal-title":"Indian J Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/11795514221074663","article-title":"Position of sulfonylureas in the current ERA: review of national and international guidelines","volume":"15","author":"Mohan V","year":"2022","unstructured":"Mohan V, Saboo B, Khader J, Modi KD, Jindal S, Wangnoo SK, Amarnath S. Position of sulfonylureas in the current ERA: review of national and international guidelines. Clin Med Insights Endocrinol Diabetes. 2022, 15:11795514221074663. 10.1177\/11795514221074663","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref19","unstructured":"IDF clinical practice recommendations for managing type 2 diabetes in primary care. (2018). Accessed. June 2, 2026: https:\/\/idf.org\/news-and-resources\/resources\/idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-pr...."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20251937","article-title":"GLIMPSE study: exploring the effectiveness of glimepiride and metformin combination therapy in newly diagnosed type 2 diabetes in India","volume":"12","author":"Mayabhate M","year":"2025","unstructured":"Mayabhate M, Kapure N, Sharma A. GLIMPSE study: exploring the effectiveness of glimepiride and metformin combination therapy in newly diagnosed type 2 diabetes in India. Int J Adv Med. 2025, 12:387-94. 10.18203\/2349-3933.ijam20251937","journal-title":"Int J Adv Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.30574\/wjarr.2025.25.2.0445","article-title":"Assessing the efficacy and safety of combined glimepiride and metformin therapy in type 2 diabetes mellitus management","volume":"25","author":"Sah RP","year":"2025","unstructured":"Sah RP, Paudel P, Thapa S, Shrestha MR, Shrestha M, Poudyal S, Mahule A. Assessing the efficacy and safety of combined glimepiride and metformin therapy in type 2 diabetes mellitus management. World J Adv Res Rev. 2025, 25:1984-92. 10.30574\/wjarr.2025.25.2.0445","journal-title":"World J Adv Res Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/ijdt.ijdt_23_24","article-title":"Usage of glimepiride and metformin combination in type 2 diabetes patients with established complications in Indian settings","volume":"3","author":"Sheikh S","year":"2024","unstructured":"Sheikh S, Nagendra L, Sinha B, et al.. Usage of glimepiride and metformin combination in type 2 diabetes patients with established complications in Indian settings. Int J Diabetes Technol. 2024, 3:74-9. 10.4103\/ijdt.ijdt_23_24","journal-title":"Int J Diabetes Technol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_22_19","article-title":"A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus","volume":"8","author":"Tandon T","year":"2019","unstructured":"Tandon T, Dubey AK, Srivastava S, Manocha S, Arora E, Hasan N. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. J Family Med Prim Care. 2019, 8:955-9. 10.4103\/jfmpc.jfmpc_22_19","journal-title":"J Family Med Prim Care"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-025-01577-w","article-title":"The association between duration of metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis","volume":"24","author":"Bahardoust M","year":"2025","unstructured":"Bahardoust M, Mehrabi Y, Hadaegh F, Azizi F, Khalili D, Delpisheh A. The association between duration of metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis. J Diabetes Metab Disord. 2025, 24:94. 10.1007\/s40200-025-01577-w","journal-title":"J Diabetes Metab Disord"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14865","article-title":"Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register","volume":"25","author":"Lim LL","year":"2023","unstructured":"Lim LL, Lau ES, Cheung JT, et al.. Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register. Diabetes Obes Metab. 2023, 25:208-21. 10.1111\/dom.14865","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.13.2.S86","article-title":"Use of sulfonylurea drugs in elderly patients","volume":"13","author":"Halter JB","year":"1990","unstructured":"Halter JB, Morrow LA. Use of sulfonylurea drugs in elderly patients. Diabetes Care. 1990, 13:86-92. 10.2337\/diacare.13.2.S86","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199303060-00005","article-title":"Problems and pitfalls of sulphonylurea therapy in older patients","volume":"3","author":"Robertson DA","year":"1993","unstructured":"Robertson DA, Home PD. Problems and pitfalls of sulphonylurea therapy in older patients. Drugs Aging. 1993, 3:510-24. 10.2165\/00002512-199303060-00005","journal-title":"Drugs Aging"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01002-4","article-title":"The position of gliclazide in the evolving landscapes and disease continuum of T2DM: a collaborative Delphi survey-based consensus from India","volume":"12","author":"Kalra S","year":"2021","unstructured":"Kalra S, Unnikrishnan AG, Bantwal G, Das S, Polavarapu NK, Gaurav K. The position of gliclazide in the evolving landscapes and disease continuum of T2DM: a collaborative Delphi survey-based consensus from India. Diabetes Ther. 2021, 12:679-95. 10.1007\/s13300-021-01002-4","journal-title":"Diabetes Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-023-01192-6","article-title":"Time to reposition sulfonylureas in type 2 diabetes management in Indian context: a pragmatic practical approach","author":"Das AK","year":"2023","unstructured":"Das AK, Saboo B, Chawla R, et al.. Time to reposition sulfonylureas in type 2 diabetes management in Indian context: a pragmatic practical approach. Int J Diabetes Dev Ctries. 2023, 1-19. 10.1007\/s13410-023-01192-6","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12605","article-title":"Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis","volume":"69","author":"Amate JM","year":"2015","unstructured":"Amate JM, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, Gonzalez-Canudas J. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta-analysis. Int J Clin Pract. 2015, 69:292-304. 10.1111\/ijcp.12605","journal-title":"Int J Clin Pract"},{"key":"ref31","article-title":"Effectiveness of glimepiride and metformin fixed-dose combination therapy in patients with type 2 diabetes and comorbidities","volume":"13","author":"Joseph K","year":"2025","unstructured":"Joseph K, Upadhyaya MK, Rahul RK, Gandhi AP, Thakker HH, Memon SS, Pandey JS. Effectiveness of glimepiride and metformin fixed-dose combination therapy in patients with type 2 diabetes and comorbidities. Int J Sci Stud. 2025, 13:10-7.","journal-title":"Int J Sci Stud"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.149334","article-title":"Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus","volume":"19","author":"George J","year":"2015","unstructured":"George J. Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus. Indian J Endocrinol Metab. 2015, 19:309. 10.4103\/2230-8210.149334","journal-title":"Indian J Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_176_17","article-title":"Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial - START study","volume":"21","author":"Devarajan TV","year":"2017","unstructured":"Devarajan TV, Venkataraman S, Kandasamy N, Oomman A, Boorugu HK, Karuppiah SK, Balat D. Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial - START study. Indian J Endocrinol Metab. 2017, 21:745-50. 10.4103\/ijem.IJEM_176_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10700","article-title":"Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence","volume":"12","author":"Sahay RK","year":"2020","unstructured":"Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G, Abhyankar M, Revenkar S. Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence. Cureus. 2020, 12:e10700. 10.7759\/cureus.10700","journal-title":"Cureus"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1901","article-title":"Second-line agents for glycemic control for type 2 diabetes: are newer agents better?","volume":"37","author":"Zhang Y","year":"2014","unstructured":"Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Denton BT. Second-line agents for glycemic control for type 2 diabetes: are newer agents better?. Diabetes Care. 2014, 37:1338-45. 10.2337\/dc13-1901","journal-title":"Diabetes Care"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwad084","article-title":"Glimepiride: an old antidiabetic medication with potential as a new cardiovascular therapeutic?","volume":"30","author":"Sawami K","year":"2023","unstructured":"Sawami K, Tanaka A, Node K. Glimepiride: an old antidiabetic medication with potential as a new cardiovascular therapeutic?. Eur J Prev Cardiol. 2023, 30:e46-7. 10.1093\/eurjpc\/zwad084","journal-title":"Eur J Prev Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE, et al.. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019, 322:1155-66. 10.1001\/jama.2019.13772","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes","volume":"387","author":"Nathan DM","year":"2022","unstructured":"Nathan DM, Lachin JM, Bebu I, et al.. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med. 2022, 387:1075-88. 10.1056\/NEJMoa2200436","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-1238","article-title":"Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study","volume":"46","author":"Wang H","year":"2023","unstructured":"Wang H, Cordiner RL, Huang Y, et al.. Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study. Diabetes Care. 2023, 46:967-77. 10.2337\/dc22-1238","journal-title":"Diabetes Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwac312","article-title":"Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study","author":"He W","year":"2022","unstructured":"He W, Yuan G, Han Y, et al.. Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study. Eur J Prev Cardiol. 2022, zwac312. 10.1093\/eurjpc\/zwac312","journal-title":"Eur J Prev Cardiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0034","article-title":"A verdict for glimepiride: effective and not guilty of cardiovascular harm","volume":"42","author":"Riddle MC","year":"2019","unstructured":"Riddle MC. A verdict for glimepiride: effective and not guilty of cardiovascular harm. Diabetes Care. 2019, 42:2161-3. 10.2337\/dci19-0034","journal-title":"Diabetes Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1487","article-title":"Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the GRADE randomized clinical trial","volume":"183","author":"Wexler DJ","year":"2023","unstructured":"Wexler DJ, de Boer IH, Ghosh A, et al.. Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the GRADE randomized clinical trial. JAMA Intern Med. 2023, 183:705-14. 10.1001\/jamainternmed.2023.1487","journal-title":"JAMA Intern Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12800","article-title":"Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies","volume":"40","author":"Chong K","year":"2024","unstructured":"Chong K, Chang JK, Chuang LM. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. Kaohsiung J Med Sci. 2024, 40:212-20. 10.1002\/kjm2.12800","journal-title":"Kaohsiung J Med Sci"},{"key":"ref44","article-title":"Usage of low-dose glimepiride (0.5 mg) and metformin combination in the management of type 2 diabetes continuum in Indian setting","volume":"23","author":"Jain P","year":"2022","unstructured":"Jain P, Kasliwal R, Singh SK, et al.. Usage of low-dose glimepiride (0.5 mg) and metformin combination in the management of type 2 diabetes continuum in Indian setting. Asian J Diabetol. 2022, 23:8-19.","journal-title":"Asian J Diabetol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13020","article-title":"Real-world observational study of glimepiride and metformin fixed-dose combination along with insulin in the management of type 2 diabetes mellitus: Indian experience","volume":"13","author":"Prasanna Kumar KM","year":"2021","unstructured":"Prasanna Kumar KM, Seshadri K, Aravind SR, et al.. Real-world observational study of glimepiride and metformin fixed-dose combination along with insulin in the management of type 2 diabetes mellitus: Indian experience. Cureus. 2021, 13:e13020. 10.7759\/cureus.13020","journal-title":"Cureus"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2008.09.002","article-title":"Efficacy of glimepiride\/metformin combination versus glibenclamide\/metformin in patients with uncontrolled type 2 diabetes mellitus","volume":"23","author":"Gonz\u00e1lez-Ortiz M","year":"2009","unstructured":"Gonz\u00e1lez-Ortiz M, Guerrero-Romero JF, Violante-Ortiz R, et al.. Efficacy of glimepiride\/metformin combination versus glibenclamide\/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009, 23:376-9. 10.1016\/j.jdiacomp.2008.09.002","journal-title":"J Diabetes Complications"},{"key":"ref47","article-title":"Usage of glimepiride and metformin combination in young adults (below 30 years of age) with type 2 diabetes mellitus in Indian settings","volume":"14","author":"Gopal K","year":"2025","unstructured":"Gopal K, Singh SK, Bhardwaj VK, et al.. Usage of glimepiride and metformin combination in young adults (below 30 years of age) with type 2 diabetes mellitus in Indian settings. Glob J Res Anal. 2025, 14:39-44.","journal-title":"Glob J Res Anal"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-025-01596-6","article-title":"Glimepiride & metformin FDC along with metformin + dapagliflozin + sitagliptin FDC in T2DM patients with high-risk CKD - Indian real world evidence study: GRACE CKD","volume":"0","author":"Murthy LS","year":"2025","unstructured":"Murthy LS, Jain A, Katakam L, et al.. Glimepiride &amp; metformin FDC along with metformin + dapagliflozin + sitagliptin FDC in T2DM patients with high-risk CKD - Indian real world evidence study: GRACE CKD. Int J Diabetes Dev Ctries. 2025, 0:0. 10.1007\/s13410-025-01596-6","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022, 45:3075-90. 10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct155","article-title":"Metformin use in chronic kidney disease: new evidence to guide dosing","volume":"106","author":"Herrington WG","year":"2013","unstructured":"Herrington WG, Nye HJ, Aung T. Metformin use in chronic kidney disease: new evidence to guide dosing. QJM. 2013, 106:1059-61. 10.1093\/qjmed\/hct155","journal-title":"QJM"},{"key":"ref51","article-title":"Glimepiride: evidence-based facts, trends, and observations (GIFTS) (corrected)","volume":"8","author":"Basit A","year":"2012","unstructured":"Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS) (corrected). Vasc Health Risk Manag. 2012, 8:463-72.","journal-title":"Vasc Health Risk Manag"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_372_24","article-title":"Efficacy and safety of gliclazide versus glimepiride in T2DM patients: a systematic review","volume":"29","author":"Bansal R","year":"2025","unstructured":"Bansal R, Kant R, Bahurupi Y, Gupta A. Efficacy and safety of gliclazide versus glimepiride in T2DM patients: a systematic review. Indian J Endocrinol Metab. 2025, 29:260-7. 10.4103\/ijem.ijem_372_24","journal-title":"Indian J Endocrinol Metab"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1554","article-title":"Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study","volume":"30","author":"Gottschalk M","year":"2007","unstructured":"Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007, 30:790-4. 10.2337\/dc06-1554","journal-title":"Diabetes Care"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2005.10.024","article-title":"Comparative efficacy of glimepiride and\/or metformin with insulin in type 2 diabetes","volume":"72","author":"Kabadi UM","year":"2006","unstructured":"Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and\/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract. 2006, 72:265-70. 10.1016\/j.diabres.2005.10.024","journal-title":"Diabetes Res Clin Pract"},{"key":"ref55","unstructured":"Metformin hydrochloride market. (2026). Accessed. June 2, 2026: https:\/\/www.marketresearchfuture.com\/reports\/metformin-hydrochloride-market-27840."},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00733-9","article-title":"Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment","volume":"11","author":"Mohan V","year":"2020","unstructured":"Mohan V, Khunti K, Chan SP, et al.. Management of type 2 diabetes in developing countries: balancing optimal glycaemic control and outcomes with affordability and accessibility to treatment. Diabetes Ther. 2020, 11:15-35. 10.1007\/s13300-019-00733-9","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/471359-repositioning-tradition-a-narrative-review-and-expert-opinion-on-the-clinical-positioning-of-glimepiride-and-metformin-in-nepals-type-2-diabetes-mellitus-t2dm-landscape","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:45:16Z","timestamp":1781250316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/471359-repositioning-tradition-a-narrative-review-and-expert-opinion-on-the-clinical-positioning-of-glimepiride-and-metformin-in-nepals-type-2-diabetes-mellitus-t2dm-landscape"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.110712","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}